Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680225 · ClinicalTrials.gov registry record · Phase 3
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
A Phase 3 study, sponsored by New England Retina Associates.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT00680225 is a Phase 3 study that has completed, run by New England Retina Associates. The registered enrollment target is 10 participants.
The verdict
NCT00680225, a Phase 3 study, has completed, sponsored by New England Retina Associates.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
Interventions
- DRUG Ranibizumab injection and TTT - ICG based
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680225
The ClinicalTrials.gov registry entry for NCT00680225 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New England Retina Associates, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab injection and TTT - ICG based is the first listed.
NCT00680225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00680225 about?
NCT00680225 is a clinical study titled "Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma". To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
What is the current status of trial NCT00680225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2007-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00680225?
The interventions under investigation include: Ranibizumab injection and TTT - ICG based (DRUG).
Who is sponsoring clinical trial NCT00680225?
This trial is sponsored by New England Retina Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.